Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study

INTRODUCTION: Fingolimod was the first oral therapy approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Due to its action on cardiac sphingosine 1-phosphate receptors, fingolimod is leading to a transient decrease in heart rate (HR) and the occurrence of rare and asymptomati...

Descripción completa

Detalles Bibliográficos
Autores principales: Linker, Ralf A., Wendt, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130918/
https://www.ncbi.nlm.nih.gov/pubmed/27624575
http://dx.doi.org/10.1007/s40120-016-0051-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130918/
https://www.ncbi.nlm.nih.gov/pubmed/27624575
http://dx.doi.org/10.1007/s40120-016-0051-7

Ejemplares similares